Piper Sandler Maintains Turnstone Biologics(TSBX.US) With Buy Rating, Maintains Target Price $20

Piper Sandler analyst Joseph Catanzaro maintains $Turnstone Biologics(TSBX.US)$ with a buy rating, and maintains the target price at $20.According to TipRanks data, the analyst has a success rate of 3

moomoo NewsMay 24 07:33 ET

Piper Sandler Sticks to Its Buy Rating for Turnstone Biologics Corp. (TSBX)

TipRanksMay 24 06:46 ET

12 Health Care Stocks Moving In Monday's After-Market Session

GainersLarimar Therapeutics (NASDAQ:LRMR) stock increased by 23.6% to $8.99 during Monday's after-market session. The company's market cap stands at $573.5 million. GT Biopharma (NASDAQ:GTBP) stock ro

BenzingaMay 20 16:31 ET

12 Health Care Stocks Moving In Thursday's After-Market Session

GainersScorpius Holdings (AMEX:SCPX) shares rose 20.9% to $0.12 during Thursday's after-market session. The market value of their outstanding shares is at $4.3 million. Kintara Therapeutics (NASDAQ:KT

BenzingaMay 16 16:31 ET

Leerink Partners Reaffirms Their Hold Rating on Turnstone Biologics Corp. (TSBX)

TipRanksMay 16 04:14 ET

Turnstone Biologics | 10-Q: Quarterly report

SEC announcementMay 13 17:10 ET · Announcements